Is It Too Late To Consider Ligand Pharmaceuticals (LGND) After Its 97% One-Year Surge?

Simply Wall St.

May 19

Investors may be wondering if Ligand Pharmaceuticals at US$207.89 is still offering value after a strong run, or if the easy gains are already behind it. The stock is up 97.4% over the past year and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2636856304"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2636856304\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2636856304?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-05-19 19:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636856304","market":"hk","top_or_hot":-1,"title":"Is It Too Late To Consider Ligand Pharmaceuticals (LGND) After Its 97% One-Year Surge?","media":"Simply Wall St.","content":"<div>\n<p>Investors may be wondering if Ligand Pharmaceuticals at US$207.89 is still offering value after a strong run, or if the easy gains are already behind it. The stock is up 97.4% over the past year and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals/news/is-it-too-late-to-consider-ligand-pharmaceuticals-lgnd-after-1\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Too Late To Consider Ligand Pharmaceuticals (LGND) After Its 97% One-Year Surge?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Too Late To Consider Ligand Pharmaceuticals (LGND) After Its 97% One-Year Surge?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-19 19:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals/news/is-it-too-late-to-consider-ligand-pharmaceuticals-lgnd-after-1><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors may be wondering if Ligand Pharmaceuticals at US$207.89 is still offering value after a strong run, or if the easy gains are already behind it. The stock is up 97.4% over the past year and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals/news/is-it-too-late-to-consider-ligand-pharmaceuticals-lgnd-after-1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1559883803.SGD","symbol_name":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals/news/is-it-too-late-to-consider-ligand-pharmaceuticals-lgnd-after-1","article_id":"2636856304","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals/news/is-it-too-late-to-consider-ligand-pharmaceuticals-lgnd-after-1","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2636856304","pubTimestamp":1779189682,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Investors may be wondering if Ligand Pharmaceuticals at US$207.89 is still offering value after a strong run, or if the easy gains are already behind it.\nThe stock is up 97.4% over the past year and 175.9% over three years, even though it has fallen 5.7% over the last week and 10.3% over the past month. It has gained 9.4% so far this year.\nRecent headlines have focused on Ligand Pharmaceuticals as a platform business in the wider pharmaceuticals and biotech space, with attention on how its...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","BK4139":"生物科技","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","LGND":"Ligand Pharmaceuticals Inc.","BK4007":"制药","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","LU0566484027.USD":"安本美国小盘成长股"},"translate_title":"Ligand Pharmaceuticals(LGND)一年飙升97%后，现在考虑是否为时已晚？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"LGND":1.5},"content_text":"Investors may be wondering if Ligand Pharmaceuticals at US$207.89 is still offering value after a strong run, or if the easy gains are already behind it. The stock is up 97.4% over the past year and 175.9% over three years, even though it has fallen 5.7% over the last week and 10.3% over the past month. It has gained 9.4% so far this year. Recent headlines have focused on Ligand Pharmaceuticals as a platform business in the wider pharmaceuticals and biotech space, with attention on how its portfolio approach and licensing model position it within the sector. At the same time, investors have been weighing how this business profile fits with their own risk tolerance, which helps explain some of the recent share price swings. Right now Ligand Pharmaceuticals has a valuation score of 4 out of 6. The next sections will compare what different valuation approaches say about the stock and then finish with a framework that can help you make even more sense of those numbers.  Ligand Pharmaceuticals delivered 97.4% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry. AdvertisementApproach 1: Ligand Pharmaceuticals Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow model estimates what a stock could be worth by projecting the cash the company might generate in the future and then discounting those amounts back to today. For Ligand Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flows in $. The latest twelve month free cash flow is about $121.8 million. Analysts have provided free cash flow estimates through 2030, with Simply Wall St extending the projections further, for example to a projected $287.7 million in 2030 before discounting. Bringing all those projected cash flows back to present value gives an estimated intrinsic value of about $377.63 per share. Compared with the recent share price of US$207.89, this suggests the stock trades at a 44.9% discount to that DCF estimate, which indicates undervaluation on this model alone. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Ligand Pharmaceuticals is undervalued by 44.9%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks. LGND Discounted Cash Flow as at May 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Ligand Pharmaceuticals. Approach 2: Ligand Pharmaceuticals Price vs Earnings For a profitable company, the P/E ratio is a useful shortcut because it links what you pay for the stock directly to the earnings it generates. Investors usually accept a higher P/E when they expect stronger growth or see lower risk, and look for a lower P/E when growth is modest or risks feel higher. Ligand Pharmaceuticals currently trades on a P/E of 27.1x. That is above the Pharmaceuticals industry average P/E of about 15.1x, yet below the peer group average of 47.5x, which shows how wide the valuation range can be in this sector. To give a more tailored view, Simply Wall St calculates a Fair Ratio, which is the P/E multiple suggested for the company after considering its earnings growth profile, profit margins, industry, market cap and company specific risks. Ligand Pharmaceuticals Fair Ratio is 17.8x, which is lower than its current 27.1x P/E. Because the Fair Ratio accounts for growth, risks and profitability rather than just broad peer or industry comparisons, it can offer a more company specific reference point. On this basis, the stock currently screens as expensive relative to that Fair Ratio. Result: OVERVALUED NasdaqGM:LGND P/E Ratio as at May 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies. Upgrade Your Decision Making: Choose your Ligand Pharmaceuticals Narrative Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St give you a clear story for a company like Ligand Pharmaceuticals, link that story to explicit forecasts for revenue, earnings and margins, then turn those assumptions into a fair value you can compare with today’s share price. This can help you decide whether the stock looks attractive or stretched. Each Narrative lives on the Community page, updates automatically as new news or earnings arrive, and accommodates very different viewpoints. For example, one investor might lean toward the higher analyst targets around US$282 with earnings closer to the upper estimate of US$557.1 million, while another might align with the lower targets near US$220 and earnings closer to US$121.1 million. Both can see how their own Narrative translates into a single fair value number beside the live market price. Do you think there's more to the story for Ligand Pharmaceuticals? Head over to our Community to see what others are saying! NasdaqGM:LGND 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}